|
1
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Olszewski AJ, Treon SP and Castillo JJ:
Evolution of management and outcomes in Waldenström
macroglobulinemia: A population-based analysis. Oncologist.
21:1377–1386. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Vijay A and Gertz MA: Waldenström
macroglobulinemia. Blood. 109:5096–5103. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zheng L, Zeng Z, Lin J and Chen J: IgM
multiple myeloma presenting with bleeding tendency: A case report
with immunophenotype analysis. Oncol Lett. 2:55–57. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wang Q, Liu Q, Liang H and Gao W: Biclonal
lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated
with POEMS syndrome: A case report and literature review. Oncol
Lett. 25(97)2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Dimopoulos MA, Kyle RA, Anagnostopoulos A
and Treon SP: Diagnosis and management of Waldenstrom's
macroglobulinemia. J Clin Oncol. 23:1564–1577. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dimopoulos MA, Merlini G, Leblond V,
Anagnostopoulos A and Alexanian R: How we treat Waldenstrom's
macroglobulinemia. Haematologica. 90:117–125. 2005.PubMed/NCBI
|
|
8
|
Oza A and Rajkumar SV: Waldenstrom
macroglobulinemia: Prognosis and management. Blood Cancer J.
5(e391)2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Grunenberg A and Buske C: How to manage
waldenström's macroglobulinemia in 2024. Cancer Treat Rev.
125(102715)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Castillo JJ and Treon SP: What is new in
the treatment of Waldenstrom macroglobulinemia? Leukemia.
33:2555–2562. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hodge LS and Ansell SM: Waldenström's
macroglobulinemia: Treatment approaches for newly diagnosed and
relapsed disease. Transfus Apher Sci. 49:19–23. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gertz MA: Waldenström macroglobulinemia:
2023 Update on diagnosis, risk stratification, and management. Am J
Hematol. 98:348–358. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lu R and Richards T: A focus on
Waldenström macroglobulinemia and AL amyloidosis. J Adv Pract
Oncol. 13 (Suppl 4):S45–S56. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Merlini G, Sarosiek S, Benevolo G, Cao X,
Dimopoulos M, Garcia-Sanz R, Gatt ME, Fernandez de Larrea C,
San-Miguel J, Treon SP and Minnema MC: Report of consensus panel 6
from the 11 th international workshop on Waldenström's
macroglobulinemia on management of Waldenström's macroglobulinemia
related amyloidosis. Semin Hematol. 60:113–117. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rubin J and Maurer MS: Cardiac
amyloidosis: Overlooked, underappreciated, and treatable. Annu Rev
Med. 71:203–219. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sethi S, Vrana JA, Theis JD, Leung N,
Sethi A, Nasr SH, Fervenza FC, Cornell LD, Fidler ME and Dogan A:
Laser microdissection and mass spectrometry-based proteomics aids
the diagnosis and typing of renal amyloidosis. Kidney Int.
82:226–234. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yi S and Li J: Chinese expert consensus on
diagnosis and treatment of lymphatic plasma cell
lymphoma/fahrenheit megaglobulinemia (2022 edition). Chin J
Hematol. 43:624–630. 2022.(In Chinese).
|
|
18
|
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao
Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, et al: MYD88
L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J
Med. 367:826–833. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
García-Sanz R, García-Álvarez M, Medina A,
Askari E, González-Calle V, Casanova M, de la Torre-Loizaga I,
Escalante-Barrigón F, Bastos-Boente M, Bárez A, et al: Clonal
architecture and evolutionary history of Waldenström's
macroglobulinemia at the single-cell level. Dis Model Mech.
16(dmm050227)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qiu Y, Wang XS, Yao Y, Si YM, Wang XZ, Jia
MN, Zhou DB, Yu J, Cao XX and Li J: Single-cell transcriptome
analysis reveals stem cell-like subsets in the progression of
Waldenström's macroglobulinemia. Exp Hematol Oncol.
12(18)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Leleu X, Hunter ZR, Xu L, Roccaro AM,
Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S,
Ho AW, et al: Expression of regulatory genes for lymphoplasmacytic
cell differentiation in Waldenstrom macroglobulinemia. Br J
Haematol. 145:59–63. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Boutilier AJ, Huang L and Elsawa SF:
Waldenström macroglobulinemia: Mechanisms of disease progression
and current therapies. Int J Mol Sci. 23(11145)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang H, Chen Y, Li F, Delasalle K, Wang J,
Alexanian R, Kwak L, Rustveld L, Du XL and Wang M: Temporal and
geographic variations of Waldenstrom macroglobulinemia incidence: A
large population-based study. Cancer. 118:3793–3800.
2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Castillo JJ, Olszewski AJ, Kanan S, Meid
K, Hunter ZR and Treon SP: Overall survival and competing risks of
death in patients with Waldenström macroglobulinaemia: An analysis
of the surveillance, epidemiology and end results database. Br J
Haematol. 169:81–89. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Morel P, Duhamel A, Gobbi P, Dimopoulos
MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon
SP, et al: International prognostic scoring system for Waldenstrom
macroglobulinemia. Blood. 113:4163–4170. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Aimo A, Merlo M, Porcari A, Georgiopoulos
G, Pagura L, Vergaro G, Sinagra G, Emdin M and Rapezz C: Redefining
the epidemiology of cardiac amyloidosis. A systematic review and
meta-analysis of screening studies. Eur J Heart Fail. 24:2342–2351.
2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Rapezzi C, Merlini G, Quarta CC, Riva L,
Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E,
et al: Systemic cardiac amyloidoses: Disease profiles and clinical
courses of the 3 main types. Circulation. 120:1203–1212.
2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Palladini G and Merlini G: Diagnostic
challenges of amyloidosis in Waldenström macroglobulinemia. Clin
Lymphoma Myeloma Leuk. 13:244–246. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wechalekar AD, Lachmann HJ, Goodman HJ,
Bradwell A, Hawkins PN and Gillmore JD: AL amyloidosis associated
with IgM paraproteinemia: Clinical profile and treatment outcome.
Blood. 112:4009–4016. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Palladini G, Russo P, Bosoni T, Sarais G,
Lavatelli F, Foli A, Bragotti LZ, Perfetti V, Obici L, Bergesio F,
et al: AL amyloidosis associated with IgM monoclonal protein: A
distinct clinical entity. Clin Lymphoma Myeloma. 9:80–83.
2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gertz MA, Merlini G and Treon SP:
Amyloidosis and Waldenström's Macroglobulinemia. Hematology Am Soc
Hematol Educ Program. 2004:257–282. 2004.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gertz MA, Kyle RA and Noel P: Primary
systemic amyloidosis: A rare complication of immunoglobulin M
monoclonal gammopathies and Waldenström's macroglobulinemia. J Clin
Oncol. 11:914–920. 1993.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bou Zerdan M, Valent J, Diacovo MJ, Theil
K and Chaulagain CP: Utility of Bruton's tyrosine kinase inhibitors
in light chain amyloidosis caused by lymphoplasmacytic lymphoma
(Waldenström's macroglobulinemia). Adv Adv Hematol.
2022(1182384)2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zanwar S, Abeykoon JP, Ansell SM, Gertz
MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV,
Dingli D, et al: Primary systemic amyloidosis in patients with
Waldenstrom macroglobulinemia. Leukemia. 33:790–794.
2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sidana S, Larson DP, Greipp PT, He R,
McPhail ED, Dispenzieri A, Murray DL, Dasari S, Ansell SM, Muchtar
E, et al: IgM AL amyloidosis: Delineating disease biology and
outcomes with clinical, genomic and bone marrow morphological
features. Leukemia. 34:1373–1382. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gustine JN, Szalat RE, Staron A, Joshi T,
Mendelson L, Sloan JM and Sanchorawala V: Light chain amyloidosis
associated with Waldenstrom macroglobulinemia: Treatment and
survival outcomes. Haematologica. 108:1680–1684. 2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Singh A, Geller HI, Alexander KM, Padera
RF, Mitchell RN, Dorbala S, Castillo JJ and Falk RH: True, true
unrelated? Coexistence of Waldenström macroglobulinemia and cardiac
transthyretin amyloidosis. Haematologica. 103:e374–e376.
2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
National Comprehensive Cancer Network
(NCCN). Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Version 1.2022, 2024.
|
|
39
|
Merlini G and Palladini G: Amyloidosis: Is
a cure possible? Ann Oncol. 19 (Suppl 4):iv63–iv66. 2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Charles Lobo A, Bhat V, Anandram S, Devi A
M S, Rao SS, Vinister GV, Lobo V and Reuben Ross C: Rare
complication of a rare malignancy: Case report of cardiac
amyloidosis secondary to waldenstrom macroglobulinemia. Qatar Med
J. 2022(7)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Qian X, Bakhshi H, Biswas R, Gattani R and
Kennedy JL: Concurrent waldenstrom macroglobulinemia and mutant
transthyretin cardiac amyloidosis. J Community Hosp Intern Med
Perspect. 12:95–99. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ho VV, O'Sullivan JW, Collins WJ, Ozdalga
E, Bell CF, Shah ND, Krishnam MS, Ozawa MG and Witteles RM:
Constrictive pericarditis revealing rare case of ALH amyloidosis
with underlying lymphoplasmacytic lymphoma (waldenstrom
macroglobulinemia). JACC Case Rep. 4:271–275. 2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Gustine JN, Staron A, Szalat RE, Mendelson
LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A,
et al: Predictors of hematologic response and survival with stem
cell transplantation in AL amyloidosis: A 25-year longitudinal
study. Am J Hematol. 97:1189–1199. 2022.PubMed/NCBI View Article : Google Scholar
|
